RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Brand Name :
Gadoxetic Acid, Eovist
Synonyms :
gadoxetate
Class :
Nonionic/ High Osmolality, magnetic resonance imaging contrast media
Dosage Forms & Strengths
Injectable solution
0.25 mol/L
0.025 mmol/kg IV
Do not exceed the infusion rate 10 mL/15 sec
Adverse drug reactions
Frequency Defined
1-10%
Headache (1%)
Dizziness (1%)
Nausea (1%)
Back pain (1%)
Flushing sensation (1%)
<1%
Akathisia
Chills
Dysgeusia
Altered sense of smell
Fatigue
Asthenia
Hyperhidrosis
Increased serum bilirubin
Increased blood pressure
Chest pain
Dyspnea
Pregnancy warnings:
Pregnancy Category: C
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were no enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: gadoxetate
Why do we use gadoxetate?
gadoxetate is a magnetic resonance imaging contrast media used for MRI of Liver Lesions.